Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: A meta-analysis

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL.1, 2008, Pages 1-7

  Belsey, J ^a   Krishnarajah, G ^b  

^a JB Medical Ltd   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hypoglycaemia; Meta analysis; Metformin; Sulphonylurea

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BODY WEIGHT; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT GAIN;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 43449131548     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00884.x     Document Type: Article

References (22)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004; 44: 397-405.
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. UK Department of Health. Prescribing Cost Analysis England 1998. London: National Statistics, 1999; 176.
6. UK Department of Health. Prescribing Cost Analysis England 2005. London, 2006; 183.
7. Hauber A, Gale EAM. The market in diabetes. Diabetologia 2006; 49: 247-252.
8. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care 2000; 23 (Suppl. 1): S1-S116.
9. International Diabetes Federation Clinical Guidelines Task Force. Global Guidelines for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. Available from URL: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed 17 March 2008.
10. National Diabetes Support Team. Factsheet No 15. London: NHS Clinical Governance Support Team, 2006. Available from URL: http://www.diabetes.nhs.uk/downloads/Factsheet_QOF.pdf. Accessed 17 March 2008.
11. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-834.
14. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulphonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomised double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
15. Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006; 23: 757-762.
16. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19: 673-680.
17. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006; 8: 156-163.
18. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167-174.
19. Inzucchi SE. Oral antihyperglycaemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
20. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38: 636-641.
21. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycaemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997; 20: 597-606.
22. Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulphonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996; 19: 1194-1199.